Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer

References

• International Agency for Research on Cancer- Cancer Research UK. World cancer factsheet 2014 [cited 2016 Oct 19]. Available from: http://publications.cancerresearchuk.org/downloads/Product/CS_REPORT_WORLD.pdf
   Google Scholar
• American Cancer Society. What are the key statistics about breast cancer? [Internet]. 2016 [ cited 2016 Nov 11]. Available from: http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics
   Google Scholar
• Cadoo KA, Fornier MN, Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging. 2013;57:312–321.
   PubMed Web of Science ®Google Scholar
• Metastatic Breast Cancer Network (MBCN). Incidence and incidence rates 2016 [ cited 2016 Oct 24]. Available from: http://www.mbcn.org/incidence-and-incidence-rates/
   Google Scholar
• O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3:20–29.
   PubMed Web of Science ®Google Scholar
• Schattner E. Raising the survival bar, and access to information, on metastatic cancer 2016 [ cited 2016 Nov 30]. Available from: http://www.forbes.com/sites/elaineschattner/2016/05/13/raising-the-survival-bar-and-access-to-information-on-metastatic-cancer/#658e187b41f3
   Google Scholar
• National Cancer Institute. SEER cancer statistics factsheets: breast cancer Bethesda, MD: National Cancer Institute; 2016 [cited 2016 Nov 30]. Available from: http://seer.cancer.gov/statfacts/html/breast.html
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:1672–1673.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.
   PubMed Web of Science ®Google Scholar
• Verma S, Bartlett CH, Schnell P, et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, Phase III study (PALOMA-3). Oncologist. 2016;21:1165–1175.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). 2016 ASCO Annual Meeting; J Clin Oncol. June 3–7, 2016;34(suppl; abstr 507); Chicago, IL, USA.
   Google Scholar
• Finn RS, Martin M, Rugo H, et al. Palbociclib and letrozole in advanced breast cancer. New Eng J Med. 2016;375:1925–1936.
   PubMed Web of Science ®Google Scholar
• Pramanik R, Sahoo RK, Gogia A. Neutropenia due to palbociclib: A word of caution? Indian J Med Paediatr Oncol. 2016;37:206.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Ettl J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016;18:67.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–439.
   PubMed Web of Science ®Google Scholar
• Bese NS, Sut PA, Ober A. The effect of treatment interruptions in the postoperative irradiation of breast cancer. Oncology. 2005;69:214–223.
   PubMed Web of Science ®Google Scholar
• Hsieh K-P, Chen L-C, Cheung K-L, et al. Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women–an Asian population-based study. PLoS One. 2014;9:e87027.
   PubMed Web of Science ®Google Scholar
• Gebbia V, Bellavia G, Ferraù F, et al. Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents. Expert Opin Drug Saf. 2012;11 Suppl 1:S49–59.
   PubMed Web of Science ®Google Scholar
• Odermatt R, Wolfer A, Zaman K. [Endocrine therapy in breast cancer: efficacy and adverse events]. Rev Med Suisse. 2013;9:1090–1094.
   PubMedGoogle Scholar
• Chiatti C, Bustacchini S, Furneri G, et al. The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people: a systematic review. Drug Saf. 2012;35 Suppl 1:73–87.
   PubMed Web of Science ®Google Scholar
• Cribb N, Merali T, Donato BMK. Impact of treatment strategies on clinical outcomes in chronic phase chronic myeloid leukemia (CP-CML) patients in Canada. Blood. 2015;116:2569.
   Google Scholar
• Porta C, Levy A, Hawkins R, et al. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med. 2014;3:1517–1526.
   PubMed Web of Science ®Google Scholar
• Law AV, Sakharkar P, Zargarzadeh A, et al. Taking stock of medication wastage: unused medications in US households. Res Social Adm Pharm. 2015;11:571–578.
   PubMed Web of Science ®Google Scholar
• Patt DA, Mitra D, Harrell RK, et al. Early treatment utilization of palbociclib for metastatic breast cancer in a US community oncology network. J Clin Oncol 34, 2016 (suppl; abstr e18112). 2016 ASCO Annual Meeting; 2016 Jun; Chicago, IL, USA.
   Google Scholar
• Baird JA, Starner CI, Bowen K, et al. Palbociclib (Ibrance) utilization and costs among 18 million insured Americans: managed care pharmacy oppertunities. AMCP Annual Meeting; 2015 Oct 27; Orlando, FL, USA.
   Google Scholar
• Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012. Curr Med Res Opin. 2014;30:1537–1545.
   PubMed Web of Science ®Google Scholar
• Li N, Hao Y, Kageleiry A, et al. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. Curr Med Res Opin. 2016;32:385–394.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
   PubMed Web of Science ®Google Scholar
• Truven Health Analytics. Red book- drug wholesale acquision price (WAC) 2016 [cited 2016 Nov 23]. Available from: http://micromedex.com/products/product-suites/clinical-knowledge/redbook
   Google Scholar
• United States Food and Drug Administration (FDA). Highlights of prescribing information, IBRANCE (palbociclib) 2015 [November 30, 2016]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf.
   Google Scholar
• Hsieh K-P, Chen L-C, Cheung K-L, et al. A competing risk analysis of hormone therapy interruption in Asian women with breast cancer. Pharmacoepidemiol Drug Saf. 2015;24:301–309.
   PubMed Web of Science ®Google Scholar
• National Health Services (United Kingdom). Medicines optimisation: the evidence in practice [Online Report]. [ cited 2016 Nov 16]. Available from: https://www.rpharms.com/promoting-pharmacy-pdfs/mo—evidence-in-practice.pdf
   Google Scholar
• Wu JJ, Zhao Y, Tran M, et al. Real world use of secukinumab among patients with psoriasis: patient characteristics and dosing. ISPOR 21st Annual International Meeting; 2016 May 21–25; Washington, DC, USA.
   Google Scholar